What's new
Fantasy Football - Footballguys Forums

This is a sample guest message. Register a free account today to become a member! Once signed in, you'll be able to participate on this site by adding your own topics and posts, as well as connect with other members through your own private inbox!

Stock Thread (56 Viewers)

2. If you put in a "good until cancelled" order to sell your CYDY stock with a limit order of $100/share, then those shares can't be shorted.  I thought permission had to be given to short shares but people are saying that the big companies like Fidelity and Schwab can short shares without permission unless a limit order exists on the shares.
Hah fat chance I am settling for $100/share on this bud.  That's a dangerous game you're playing there.  What if CYDY spikes to $500/share at the open tomorrow and your chump #### got stuck selling for $100.

 
BassNBrew said:
BassNBrew said:
Ex-dividend date on DHT is 5-18-20.  Can someone explain when I need to buy and how long I need to hold to capture that dividend?
bump
You need to own it on the day prior to the ex-dividend date, but It doesn't really matter- the stock drops by the amount of the dividend anyway, it isn't "free money" as some seem to think.

 
Todem said:
I am not going to just get on board that all people are going to want to work from home. I am counting the days to get back into the office....and I can do my job perfectly from home. While I get this shift....I think some are way overstating it long term. That is what I believe. 

Productivity  IMO will also dictate this and IMO productivity for most people at home does not match at the office. We can go back and forth till we are blue in the face....so we can agree to disagree. 
This. I think what is most permanent is CEO’s/CFO’s seeing what can be done with less travel expense. I don’t think that ever comes back the same. But while there is an acceptance that work from home is necessary now I believe it will swing to the other side. Leadership will think company culture can’t be formed or continued. And they want to SEE people working. There will be a backlash against people who resist coming back to the office. They will be looked at as slackers. Once there is a vaccine all bets are off. See you on Monday in the office. 

 
FreeBaGeL said:
Hah fat chance I am settling for $100/share on this bud.  That's a dangerous game you're playing there.  What if CYDY spikes to $500/share at the open tomorrow and your chump #### got stuck selling for $100.
At $500 a share it would only be a $750B company.  What would we do with that?

 
Jefferson the Caregiver said:
Dr Yo seems to know his stuff. At least to this layman's ears he sounds intelligent. On the other hand, he could be like the imposter sign language guy at Nelson Mandela's funeral and I wouldn't know the difference.

Anyway, before I get too off topic, there is a point to my ramble.

The conspiracy theorist that I try to keep at Bay inside me screams that he is actually on the Cytodyn payroll and is the best guerrilla marketing campaign that NP is running.

If so, hats off to NP, it's good.

I mean isn't it a little odd that this anesthesiologist can't stop talking about leronlimab? A bit suspicious.
Could be as simple as he bought shares. Plenty of shlubs on Twitter who won't #### about it, obviously only because they're long. 

 
Could be as simple as he bought shares. Plenty of shlubs on Twitter who won't #### about it, obviously only because they're long. 
Well that's not as interesting! Although I agree that's probably the case.

Weird that Yo leaked that Patterson was going to be published in Nature last week (and was obviously wrong), feel like someone had to feed him that.  I have a guess where he got that info, starts with N and ends with P.  Unless he is just making crap up, which doesn't seem to be the case.

Keeping this conspiracy theory alive..

 
Last edited by a moderator:
caustic said:
BUD <$40 is tempting me.
I doubled down yesterday at $38.69.  It ran from $41 to $49 in 5 days a couple of weeks ago.  It was less than 1% so I foolishly ignored it rather than taking the profit.  I won't make that mistake again.  It's trading at 40% of it's value a year ago.

On another note, it's one of the examples of why I don't think the market is significantly over valued.  It's price has been crushed by sales drops due to the virus.  You have a few sectors and stocks keeping the indexes at pretty high levels while there are stocks everywhere you look trade at 50-70% discounts. 

 
You need to own it on the day prior to the ex-dividend date, but It doesn't really matter- the stock drops by the amount of the dividend anyway, it isn't "free money" as some seem to think.
I'm seeing a potential perfect storm where the earnings from other companies in the sector hit right around the time this dividend is paid.  I'm going to take the risk that DHT doesn't drop 5%.

 
Could be as simple as he bought shares. Plenty of shlubs on Twitter who won't #### about it, obviously only because they're long. 
That might be true about Dr. Umang Khetarpal but Dr Yo and Dr Mike Hanson seem completely genuine to me.  Their type of earnestness cannot be faked.  And the best reason to invest in the stock is because you believe leronlimab is potentially a miracle drug.  I would not be invested in CYDY if I did not believe in the drug.

 
CytoDyn to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19

https://www.cytodyn.com/newsroom/press-releases/detail/431/cytodyn-to-offer-no-cost-exploratory-laboratory-testing-for

May 15, 2020 6:00am EDT

VANCOUVER, Washington, May 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced it is offering comprehensive cytokine profiling (including RANTES levels) through its diagnostic partner company, IncellDx, to help physicians understand the pathogenesis of Childhood Inflammatory Disease Related to COVID-19. These laboratory tests are exploratory in nature and not intended for clinical decision making.

Recent reports in parts of the U.S. and Europe suggest a rare and potentially fatal inflammatory disease linked to the novel coronavirus is afflicting a small number of children. The condition resembles a rare childhood illness called Kawasaki disease, which has similar signs and symptoms and can lead to enlargement of blood vessels that in severe forms may cause heart damage.

New York State Department of Health is investigating 110 reported cases and 3 deaths in children - predominantly school-aged - experiencing symptoms similar to Kawasaki disease and toxic shock-like syndrome, possibly due to COVID-19.

Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostic partner and an advisor to CytoDyn commented, “Cytokines are proteins that modulate the inflammatory response. Kawasaki disease has been previously shown to be associated with elevated levels of RANTES, a protein we have shown to be significantly elevated in mild-moderate COVID-19 and over 100 times normal in critical COVID-19 patients.”

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn added, “We hope our comprehensive cytokine testing will help physicians gain a better understanding of the disease process and, in turn, explore the prospect for leronlimab to potentially provide a therapeutic benefit to children suffering from inflammatory illness related to COVID-19.”

 
Question. When something like this comes across the news...I feel like this would be a good stock (AMAT) to try and get into at its current price of $53.70 for maybe a quick turnaround. Am I Wrong? I do have a degree in Business so I am not going in blind, but I have only very recently gotten into buying individual stocks and am very much a novice.Other than a google search I did today,I have never heard of Applied Materials or B Riley.

“Applied Materials stock price target raised to $72 from $56 at B Riley FBR”

Any comments would be very much appreciated!

 
Last edited by a moderator:
CytoDyn to Offer No-Cost Exploratory Laboratory Testing for Childhood Inflammatory Disease Associated with COVID-19

https://www.cytodyn.com/newsroom/press-releases/detail/431/cytodyn-to-offer-no-cost-exploratory-laboratory-testing-for

May 15, 2020 6:00am EDT

VANCOUVER, Washington, May 15, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced it is offering comprehensive cytokine profiling (including RANTES levels) through its diagnostic partner company, IncellDx, to help physicians understand the pathogenesis of Childhood Inflammatory Disease Related to COVID-19. These laboratory tests are exploratory in nature and not intended for clinical decision making.

Recent reports in parts of the U.S. and Europe suggest a rare and potentially fatal inflammatory disease linked to the novel coronavirus is afflicting a small number of children. The condition resembles a rare childhood illness called Kawasaki disease, which has similar signs and symptoms and can lead to enlargement of blood vessels that in severe forms may cause heart damage.

New York State Department of Health is investigating 110 reported cases and 3 deaths in children - predominantly school-aged - experiencing symptoms similar to Kawasaki disease and toxic shock-like syndrome, possibly due to COVID-19.

Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostic partner and an advisor to CytoDyn commented, “Cytokines are proteins that modulate the inflammatory response. Kawasaki disease has been previously shown to be associated with elevated levels of RANTES, a protein we have shown to be significantly elevated in mild-moderate COVID-19 and over 100 times normal in critical COVID-19 patients.”

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn added, “We hope our comprehensive cytokine testing will help physicians gain a better understanding of the disease process and, in turn, explore the prospect for leronlimab to potentially provide a therapeutic benefit to children suffering from inflammatory illness related to COVID-19.”
Are they going to solve world hunger in the free time too?

 
BassNBrew said:
Anyone else feel like DOW 24k is insanely high for the times and at DOW 23k there is value everywhere?  
What is crazy is the markets are being led by top heavy stocks. So when there are these sell offs we are finding value. Like what I bought yesterday. There is excellent long term value in Industrials, materials, utilities, telecommunications. There is almost no value in Big Tech, Pharma and staples. The stay at home trade is over. I own PG and GIS, CLX,  and JNJ BTW. Have for many moons. I am tempted to start trimming CLX and GIS (I was buying more GIS at the end of 2018 in the mid 30’s, 36 and change actually, when it sold off briskly on the so called health kick, softer earnings and not eating processed foods yada yada yada..remember that BS?) I want me some lucky Charms #####es.....bought that stock hand over fist back then. We have nearly a double now in GIS (who also owns Hagan Daz BTW and they line up around the corner in China for that stuff). Also they bought Blue Buffalo which was a brilliant aquisistion that they paid a lot for. But I loved it because people feed their pets better than themselves and pay a premium for dog and cat food. So some rebalancing is going to happen within my large cap sleeve. 

And let’s not forget Big Oil. The wicked step child in this downturn. XOM, CVX are at super value levels. I have suggested many times, using PEO as a play on big oil. It is more diversified than having to pick a big oil stock and pays an outstanding dividend. It is trading at a huge discount in relation to it’s NAV (Net Asset Value) (it has popped over 35% since I recommend it back in March). 

caustic said:
CNBC reporting that the WH is becoming increasingly supportive of another round of stimulus checks.  :excited:
Some of us are not getting anything....and I get it. So we will keep paying our taxes to help those less fortunate.

caustic said:
BUD <$40 is tempting me.
I love TAP. I can’t stand BUD’s management. Company is not well run anymore since that Inbev merger. TAP is the beer play in my book. Bought it yesterday and it is cheap, with a great dividend. Great long term hold.

I mostly ignored all the onion talk. Is the goal with it pretty strictly a quick 20% and out around $10.80 (assuming $9 buyers)
My goal is to see $13. That will be a nice trade. And it can easily get their in a big rally intra-day as the openings keep rilling out around the country and the videos of crowded restaurants and waits spur positive sentiment of the “pent up” demand to go out and eat again. This is a pure momentum play stock. Strap in boys!

 
Last edited by a moderator:
Question. When something like this comes across the news...I feel like this would be a good stock (AMAT) to try and get into at its current price of $53.70 for maybe a quick turnaround. Am I Wrong? I do have a degree in Business so I am not going in blind, but I have only very recently gotten into buying individual stocks and am very much a novice.Other than a google search I did today,I have never heard of Applied Materials or B Riley.

“Applied Materials stock price target raised to $72 from $56 at B Riley FBR”

Any comments would be very much appreciated!
here are my comments, take them for what they are worth

If you have never heard of a company, you should probably do some research on them before putting money into them.

If you are gambling on a short term pop, you missed it, as it was up ~10% from yesterday. 

I've never heard of B Riley myself, but there are more financial services firms out there than I'd care to count, and any of them can adjust their target prices.  

Applied Materials is a solid company, but not really my favorite.  Is it possible the stock climbs another 5, 10, 15% in the next few weeks?  Sure, but you may want to monitor the news and this situation with China as that will most certainly have an impact on semi's.

 
@BrianRoemmele

On this day May 15, 1997 Amazon Inc. held its IPO on the Nasdaq at a price of $18 per share. $10,000 invested on that day and price would be worth more than $12 million as of May, 2020. That's more than 120,000% growth.

 
@BrianRoemmele

On this day May 15, 1997 Amazon Inc. held its IPO on the Nasdaq at a price of $18 per share. $10,000 invested on that day and price would be worth more than $12 million as of May, 2020. That's more than 120,000% growth.
Sure, but that took 23 years. OK, I guess.

But the way Bossman and I see it, if you can sell puts and generate even just a 10% return on your principal in one month (he's getting much more than that, mind you), then our $10000 in 1997 would have grown to 12 million in 75 months, more or less. We like massive returns that don't take decades.

 
Kramerica does not like anything he is hearing about BA.

BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY BUY!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

 
Sure, but that took 23 years. OK, I guess.

But the way Bossman and I see it, if you can sell puts and generate even just a 10% return on your principal in one month (he's getting much more than that, mind you), then our $10000 in 1997 would have grown to 12 million in 75 months, more or less. We like massive returns that don't take decades.
I'd subscribe to your newsletter, except I know that selling naked puts works....until it doesn't.

 
That might be true about Dr. Umang Khetarpal but Dr Yo and Dr Mike Hanson seem completely genuine to me.  Their type of earnestness cannot be faked.  And the best reason to invest in the stock is because you believe leronlimab is potentially a miracle drug.  I would not be invested in CYDY if I did not believe in the drug.
I see it this way as well.  Dr. Yo is passionate (at least seems) about the science and seems like he genuinely loves to create and present his animations as part of his explanation of how the drug works.  I imagine he does have shares but I believe he genuinely believes in this drug.  

 
New article about Samantha Mottet.  It's the second story from the top on the front page of the CBN website.

'I Thank God for Giving Me Another Day': Mom Credits Little-Known Drug Leronlimab with Saving Her Life

https://www1.cbn.com/cbnnews/health/2020/may/i-thank-god-for-giving-me-another-day-mom-credits-little-known-drug-leronlimab-with-saving-her-life

Samantha Mottet started feeling extremely tired in mid-March.  Just two weeks later, she appeared near death in the Intensive Care Unit of Ronald Reagan UCLA Medical Center after testing positive for COVID-19. 

"I had moments of 'gosh, 55 years went by so fast'," she told CBN News. "I'm not going to see my children again, I'm not going to see my parents, my future grandchildren." 

The married mother of three underwent a liver transplant 14 years ago, putting her at high risk for serious complications from COVID-19. Her faith and that of her friends and family sustained her through her ordeal.

"I had overwhelming support from my friends and family praying for me," she said, "They were all praying for a miracle that I would survive this."

Samantha was treated by Dr. Otto Yang, an infectious disease specialist, who treated her with a number of experimental therapies with little success.

"She certainly had not improved," he told CBN News. "She had been on the ventilator for several days already and her condition was still critical and not improving at that point. So I thought that we didn't have much to lose."

Dr. Yang has had a longstanding interest in HIV-pathogenesis stemming from his experience at New York's Bellevue Hospital where more than half of his patients were HIV-1 infected. Because of that, he was aware of the drug leronlimab, which was originally developed to treat HIV patients and is now being used by some doctors to treat COVID-19 patients. After getting permission, Dr. Yang injected Samantha with leronlimab.

"About a day or two days later the amount of oxygen she required on a ventilator started to go down, so the amount of oxygen being exchanged in her lungs started to improve. And then a couple more days later she was able to get off the ventilator," he said, adding, "Then she went home."

Samantha feels grateful that her doctor knew about leronlimab and wishes more COVID-19 patients and their physicians were familiar with it.

"It was my last hope and if it were not for that drug I truly would not be here today," she said. 

In addition to Samantha, Dr. Yang has given leronlimab to several other patients with varying results. 

"It's been a mixture," he said. "Many of them have improved. Not everyone." 

Leronlimab was developed by the biotechnology company CytoDyn. The drug is a monoclonal antibody that CytoDyn CEO Dr. Nader Pourhassan says can calm the often deadly 'cytokine storm,' which is an extreme immune system over-reaction.

"If we can stop the death, this is just the flu. It won't do anything," he told CBN News. "The whole country can be reopened and everybody's going to be safe if this works the way we think."

The US Food and Drug Administration designated leronlimab as an Emergency Investigational New Drug or EIND.

"That requires the physician personally to contact the FDA, produce certain types of information and get approval," Dr. Yang explained. "It's fairly time consuming and it's a barrier to giving it."

Pourhassan said the time it takes to receive FDA approval is costing lives.

"People are dying right now," he said. "They're asking us for the drug and when we send it to them, on a couple of occasions they got the drug and they were dead already."

CytoDyn is asking the FDA to upgrade leronlimab for "compassionate use" and believes that will happen when the agency receives more data about its efficacy. 

"We are just hopeful to get to our trials. The FDA has immediately given us two trials, one randomized Phase 2 trial for mild and moderate, and one Phase 3 for severe population," he said. "We're enrolling as fast as we can and hoping to have results from our first 75-patient trial very quickly." 

Meanwhile, Samantha is doing all she can to spread the word. 

"I feel like my number one purpose right now is to promote leronlimab because it saved me. I just get chills sometimes when I think about how close I was to death," she said. "Every morning since I've been home, the first thing I do in the morning when I open my eyes is, I look up and put my hands together and I thank God for giving me another day and I go to bed at night thanking Him." 

 
Last edited by a moderator:
Selling Options Lesson #131

Selling Covered Calls

I'm still very new to this so please don't take this as gospel. Just expressing what I THINK I understand ... and my common sense.

Now that everyone is proficient at selling Puts   :oldunsure:  ... lets talk selling Covered Calls (most of you know this but some are new to  it)

Just like selling Puts,  you collect a premium up front ... but one difference is that you need to own the stonk to sell a covered call .. vs. selling a Put where you don't.

Selling a covered call, you're selling someone the option to buy your stonks at the strike price. They pay you for this option up front (premium).

If the stonk is above strike price at strike date, you're selling them the stock. If stonk price is below strike price at strike date, your keeping the stock.

THEY win if the stonk is above strike price since they now are buying the stonk for less than it's worth.

Either way you keep the premium ... but preferably, you want the premium AND keep the stonks. So you are rooting for the stonk to NOT TANK ... but stay below strike price.

Example;

In the latest episode of Bossman vs. Wall Street, ... Boss purchased 1000 shares of NERV @ $12.50

Same day, Sold 10 6/19 $17.50 covered calls for $3.40. Paid me $3400 (1000 shares x $3.40)

So if NERV stays below $17.50 until 6/19, I keep the stonks and the $3400 premium.

If NERV is above $17.50 on 6/19, I'm obligated to sell the stock for $17.50  ... so I made $5 a share over purchase price ($5000) and I keep the $3400 premium = $8400

Win / Win you say? ... not so fast. Here's the risk;

Should NERV fall to less than $9.10 a share, the loss in stonk value would offset the premium that I was paid ($12.50  less $3.40)

Here's where I would need to make a decision ... If the stock is falling hard before strike date, I may want to cover my short and take my lumps early ... limiting losses.

... or I could ride it out, hope the stock levels off or recovers. So again, not a "set and forget" play.

Also consider, in this scenario, the person buying my $17.50 covered calls for $3.40 would need the stonk price to be at $20.90 to make a profit.

Yes, people out there are betting LOTS OF MONEY that NERV will be above $20.90 5 weeks from now.  :shrug:

Ideal scenario for the covered call seller (Bossman) would be for the stonk price to stays in the same ballpark, $10 to $17 in this case, option expires, and he sells the covered calls again next month ... another $3400? .... and the month after, another $3400? ... and again, another $3400? .... rinse, repeat.

Each month he does this, his cost basis drops by the amount of premium he collects. Initial $12,500 investment is now a cost basis of $9100 ($12500 less $3400). Another month $5700, another $2300. Assuming it's still paying $3400 each time (not likely tho)

Keep in mind, this is an EXTREME scenario. These premiums are typically MUCH less and there is no rhyme or reason for NERV options to be trading so high.

Depending on how many times he can do this before the stonk hits strike price and gets called away ...  or tanks, could easily make 2, 3 or 4x the initial investment.

Also, you're not locked in as you have the option to cover and get out at any time.

 
Selling Options Lesson #131

Selling Covered Calls

I'm still very new to this so please don't take this as gospel. Just expressing what I THINK I understand ... and my common sense.

Now that everyone is proficient at selling Puts   :oldunsure:  ... lets talk selling Covered Calls (most of you know this but some are new to  it)

Just like selling Puts,  you collect a premium up front ... but one difference is that you need to own the stonk to sell a covered call .. vs. selling a Put where you don't.

Selling a covered call, you're selling someone the option to buy your stonks at the strike price. They pay you for this option up front (premium).

If the stonk is above strike price at strike date, you're selling them the stock. If stonk price is below strike price at strike date, your keeping the stock.

THEY win if the stonk is above strike price since they now are buying the stonk for less than it's worth.

Either way you keep the premium ... but preferably, you want the premium AND keep the stonks. So you are rooting for the stonk to NOT TANK ... but stay below strike price.

Example;

In the latest episode of Bossman vs. Wall Street, ... Boss purchased 1000 shares of NERV @ $12.50

Same day, Sold 10 6/19 $17.50 covered calls for $3.40. Paid me $3400 (1000 shares x $3.40)

So if NERV stays below $17.50 until 6/19, I keep the stonks and the $3400 premium.

If NERV is above $17.50 on 6/19, I'm obligated to sell the stock for $17.50  ... so I made $5 a share over purchase price ($5000) and I keep the $3400 premium = $8400

Win / Win you say? ... not so fast. Here's the risk;

Should NERV fall to less than $9.10 a share, the loss in stonk value would offset the premium that I was paid ($12.50  less $3.40)

Here's where I would need to make a decision ... If the stock is falling hard before strike date, I may want to cover my short and take my lumps early ... limiting losses.

... or I could ride it out, hope the stock levels off or recovers. So again, not a "set and forget" play.

Also consider, in this scenario, the person buying my $17.50 covered calls for $3.40 would need the stonk price to be at $20.90 to make a profit.

Yes, people out there are betting LOTS OF MONEY that NERV will be above $20.90 5 weeks from now.  :shrug:

Ideal scenario for the covered call seller (Bossman) would be for the stonk price to stays in the same ballpark, $10 to $17 in this case, option expires, and he sells the covered calls again next month ... another $3400? .... and the month after, another $3400? ... and again, another $3400? .... rinse, repeat.

Each month he does this, his cost basis drops by the amount of premium he collects. Initial $12,500 investment is now a cost basis of $9100 ($12500 less $3400). Another month $5700, another $2300. Assuming it's still paying $3400 each time (not likely tho)

Keep in mind, this is an EXTREME scenario. These premiums are typically MUCH less and there is no rhyme or reason for NERV options to be trading so high.

Depending on how many times he can do this before the stonk hits strike price and gets called away ...  or tanks, could easily make 2, 3 or 4x the initial investment.

Also, you're not locked in as you have the option to cover and get out at any time.
So what's the benefit to the other person?  Why dont they just buy the stock at the current price?

 
Selling Options Lesson #131

Selling Covered Calls

I'm still very new to this so please don't take this as gospel. Just expressing what I THINK I understand ... and my common sense.

Now that everyone is proficient at selling Puts   :oldunsure:  ... lets talk selling Covered Calls (most of you know this but some are new to  it)

Just like selling Puts,  you collect a premium up front ... but one difference is that you need to own the stonk to sell a covered call .. vs. selling a Put where you don't.

Selling a covered call, you're selling someone the option to buy your stonks at the strike price. They pay you for this option up front (premium).

If the stonk is above strike price at strike date, you're selling them the stock. If stonk price is below strike price at strike date, your keeping the stock.

THEY win if the stonk is above strike price since they now are buying the stonk for less than it's worth.

Either way you keep the premium ... but preferably, you want the premium AND keep the stonks. So you are rooting for the stonk to NOT TANK ... but stay below strike price.

Example;

In the latest episode of Bossman vs. Wall Street, ... Boss purchased 1000 shares of NERV @ $12.50

Same day, Sold 10 6/19 $17.50 covered calls for $3.40. Paid me $3400 (1000 shares x $3.40)

So if NERV stays below $17.50 until 6/19, I keep the stonks and the $3400 premium.

If NERV is above $17.50 on 6/19, I'm obligated to sell the stock for $17.50  ... so I made $5 a share over purchase price ($5000) and I keep the $3400 premium = $8400

Win / Win you say? ... not so fast. Here's the risk;

Should NERV fall to less than $9.10 a share, the loss in stonk value would offset the premium that I was paid ($12.50  less $3.40)

Here's where I would need to make a decision ... If the stock is falling hard before strike date, I may want to cover my short and take my lumps early ... limiting losses.

... or I could ride it out, hope the stock levels off or recovers. So again, not a "set and forget" play.

Also consider, in this scenario, the person buying my $17.50 covered calls for $3.40 would need the stonk price to be at $20.90 to make a profit.

Yes, people out there are betting LOTS OF MONEY that NERV will be above $20.90 5 weeks from now.  :shrug:

Ideal scenario for the covered call seller (Bossman) would be for the stonk price to stays in the same ballpark, $10 to $17 in this case, option expires, and he sells the covered calls again next month ... another $3400? .... and the month after, another $3400? ... and again, another $3400? .... rinse, repeat.

Each month he does this, his cost basis drops by the amount of premium he collects. Initial $12,500 investment is now a cost basis of $9100 ($12500 less $3400). Another month $5700, another $2300. Assuming it's still paying $3400 each time (not likely tho)

Keep in mind, this is an EXTREME scenario. These premiums are typically MUCH less and there is no rhyme or reason for NERV options to be trading so high.

Depending on how many times he can do this before the stonk hits strike price and gets called away ...  or tanks, could easily make 2, 3 or 4x the initial investment.

Also, you're not locked in as you have the option to cover and get out at any time.
There is a reason that the options for NERV are trading with such high premiums, that is for sure.  I think you found a good investment but there is risk of a large movement either direction.

 
Question. When something like this comes across the news...I feel like this would be a good stock (AMAT) to try and get into at its current price of $53.70 for maybe a quick turnaround. Am I Wrong? I do have a degree in Business so I am not going in blind, but I have only very recently gotten into buying individual stocks and am very much a novice.Other than a google search I did today,I have never heard of Applied Materials or B Riley.

“Applied Materials stock price target raised to $72 from $56 at B Riley FBR”

Any comments would be very much appreciated!
This is mostly just noise. Price updates are usually just the stock has moved but they want to keep their buy/sell/hold recommendation so they update the price. Usually, there has to be something like 15-20% upside to the price target for a buy so if the stock rallies too much, they need to update it. 

The bigger moves are usually the result of an upgrade or downgrade. Also, certain firms and more specifically, certain analysts will move stocks more. GS is GS so they get more press. GS/MS are known for their tech practices. And if JPM's Tusa ever turns bullish on GE, you could see a double that day. The biggest reactions to a rec change would be a double upgrade or double downgrade: from buy to sell or sell to buy and skipping past hold. Also, there is usually a bias to be long, especially at the investment banks. Most analysts rely on corporate access and banks derive money from other services so there is an implicit expectation that they won't be super negative albeit, there is some independency. You can usually get a quick pop on a recommendation change but that is a crowded trade. 

tl/dr: don't rely on analyst price changes, especially if you're looking for a quick buck. 

 
Last edited by a moderator:
So what's the benefit to the other person?  Why dont they just buy the stock at the current price?
Great question.

The person paying $3.40 to buy $17.50 calls are betting the stock will be above $20.90 at strike date.

They are only betting $3.40 vs buying the stonk for $12.50 ... so their initial investment is much less than buying the stock outright.

If it goes to $32.50 a share by 6/19 .... they invested $3.40 to make $15 ($32.50 less $17.50)

... but yeah, seems like a dumb play to me to be on that side of this deal.

 
TAP is trading pretty close to its 52 week low and not like it was going down heading into the pandemic.  I just bought a little as well and might buy more.

Side note.  Already hit 10% on BLMN since I kept buying when it was dropping to get a cost basis of 9.  

 
Last edited by a moderator:
Great question.

The person paying $3.40 to buy $17.50 calls are betting the stock will be above $20.90 at strike date.

They are only betting $3.40 vs buying the stonk for $12.50 ... so their initial investment is much less than buying the stock outright.

If it goes to $32.50 a share by 6/19 .... they invested $3.40 to make $15 ($32.50 less $17.50)

... but yeah, seems like a dumb play to me to be on that side of this deal.
The underlying stock does not even need to go to $20.90 per share. All it needs to do is rise quickly. If a stock goes up 10%, the near-the-money call options roughly double (this is my own rule of thumb and there is much variability, but I've found it to be a good rough gauge). So it is not necessarily true that the buyer of the call option believes the stock will get to that strike price by expiration but he does think the stock will rise and probably fast. A bought call option as described almost certainly would be resold (for a profit or a loss) before the expiration date.

 
On selling covered calls: I have soured to this especially lately. With such volatility in the markets, it is a good thing to be able to exit a position quickly. If you sell a covered call for one month out, sure you keep the premium. But if the stock tanks, you need to re-buy that call before you can sell the underlying. And if you get a pop in the stock price, you cannot sell and lock in that profit. Selling covered calls is the most conservative options strategy so there is a time and a place for it, but these are times where agility is important so I don't recommend selling covered calls as strongly as I would in a tepid market.

 
There is a reason that the options for NERV are trading with such high premiums, that is for sure.  I think you found a good investment but there is risk of a large movement either direction.
:goodposting:

Very true. Premiums don't pay like this unless something big is about to break.

Research as I may, hard to find any major negative news on NERV.

What I do find is that they are due to put our a report on drug study findings ... could be bad news, could be great news.

... yet so called "experts" have upgraded NERV target to $23 a share. Not sure why. News leaked? 

Maybe someone else in here can Sherlock Holmes this thing and make some sense of it.

 
@BrianRoemmele

On this day May 15, 1997 Amazon Inc. held its IPO on the Nasdaq at a price of $18 per share. $10,000 invested on that day and price would be worth more than $12 million as of May, 2020. That's more than 120,000% growth.
Yeah, thanks. I could have done that. Instead I blew almost $50000 on other stocks.

 
The underlying stock does not even need to go to $20.90 per share. All it needs to do is rise quickly. If a stock goes up 10%, the near-the-money call options roughly double (this is my own rule of thumb and there is much variability, but I've found it to be a good rough gauge). So it is not necessarily true that the buyer of the call option believes the stock will get to that strike price by expiration but he does think the stock will rise and probably fast. A bought call option as described almost certainly would be resold (for a profit or a loss) before the expiration date.
Great point and one that I don't consider.

I assume many option traders are "in and out" several times before it ever gets to strike date. 

I do love the fact that I'm able to take advantage of these type of trades.

 
And, to the question of why people buy call options, there is a one word answer: leverage. If I invest $1000 in NERV and it goes up 10%, I'm now at $1100. If I buy $1000 of call options in NERV and it goes up 10%, I'm at $2000. Higher risk, much higher reward, massive leverage.

 

Users who are viewing this thread

Back
Top